Gregory R. Mundy, MD
Mundy G.; Secondary Osteoporosis: The Potential Relevance of Leptin and Low Body Weight. Ann Intern Med. 2000;133:828-830. doi: 10.7326/0003-4819-133-10-200011210-00016
Download citation file:
Published: Ann Intern Med. 2000;133(10):828-830.
The diagnosis and treatment of osteoporosis have advanced greatly in the past 20 years. We now have effective (albeit imperfect) drugs, such as bisphosphonates, estrogen, and selective estrogen-receptor modulators, that substantially reduce fracture rates. Selective estrogen-receptor modulators may provide other benefits, such as alleviation of breast cancer risk. Because the techniques for assessment of bone mass and subsequent prediction of risk for fracture have improved, it is easier to make treatment decisions and to diagnose osteoporosis before fractures occur. This improvement in management is likely to continue during the next decade. By then, anabolic agents will be available to stimulate bone formation, and new diagnostic markers will allow clinicians to monitor treatment more effectively.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Endocrine and Metabolism, Metabolic Bone Disorders.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only